Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment.
Nicolas-Boluda A, Vaquero J, Vimeux L, Guilbert T, Barrin S, Kantari-Mimoun C, Ponzo M, Renault G, Deptula P, Pogoda K, Bucki R, Cascone I, Courty J, Fouassier L, Gazeau F, Donnadieu E. · 2021
Read Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment. by Nicolas-Boluda A, Vaquero J, Vimeux L, Guilbert T, Barrin S, Kantari-Mimoun C, Ponzo M, Renault G, Deptula P, Pogoda K, Bucki R, Cascone I, Courty J, Fouassier L, Gazeau F, Donnadieu E. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8203293.txt.
Description
Nicolas-Boluda and co-authors test whether softening a tumour helps T cells and immunotherapy. Dense matrix in tumours can wall T cells out. Only a share of patients gain from checkpoint inhibitors.
Across five mouse tumour models, stiffness rose with growth and matrix crosslinking. Stiffer tumours showed less T cell movement inside. Blocking lysyl oxidase cut collagen stabilisation and softened the tumours. T cell migration improved after that change. Anti-PD-1 treatment then worked better. The study ties a physical trait of tumours to a drug strategy. Matrix change, not just immune drugs, did part of the work.
Catalog record
| CREATOR | Nicolas-Boluda A, Vaquero J, Vimeux L, Guilbert T, Barrin S, Kantari-Mimoun C, Ponzo M, Renault G, Deptula P, Pogoda K, Bucki R, Cascone I, Courty J, Fouassier L, Gazeau F, Donnadieu E. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 94 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |